LGG-25. The first-in-class ERK inhibitor ulixertinib (BVD-523) shows activity in MAPK-driven pediatric low-grade glioma models as single agent and in combination with MEK inhibitors or senolytics

Ulixertinib (BVD-523) is a catalytic ERK1/2 inhibitor that showed promising responses in adult patients with mitogen-activated protein kinase (MAPK)-driven solid tumors. Pediatric low-grade gliomas (pLGG) are the most common pediatric brain tumors, with the most frequent driving alterations in the M...

Descripción completa

Detalles Bibliográficos
Autores principales: Sigaud, Romain, Rösch, Lisa, Gatzweiler, Charlotte, Benzel, Julia, von Soosten, Laura, Peterziel, Heike, Najafi, Sara, Ayhan, Simay, Gerloff, Xena F, Hofmann, Nina, Büdenbender, Isabel, Foerster, Kathrin I, Burhenne, Jürgen, Longuespée, Rémi, van Tilburg, Cornelis M, Jones, David T W, Pfister, Stefan M, Knoerzer, Deborah, Kreider, Brent, Sauter, Max, Pajtler, Kristian W, Zuckermann, Marc, Oehme, Ina, Witt, Olaf, Milde, Till
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Low Grade Glioma
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164732/
http://dx.doi.org/10.1093/neuonc/noac079.339

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164732/
http://dx.doi.org/10.1093/neuonc/noac079.339

Ejemplares similares